A 12-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 microg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Trial Profile

A 12-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 microg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Sinusitis
  • Focus Adverse reactions; Registrational
  • Acronyms EXHANCE-12
  • Sponsors OptiNose
  • Most Recent Events

    • 09 May 2017 According to a OptiNose media release, The FDA has set a target date to complete its review of the NDA under the Prescription Drug User Fee Act (PDUFA) of September 2017.
    • 31 Jan 2017 According to an OptiNose media release, the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for the investigational new product OPN-375.
    • 16 Sep 2016 Results from this trial were presented at the American Rhinologic Societys Annual Meeting, according to an Optinose media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top